Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study (Q40029238)

16 September 2017

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study (English)

1 reference

multicenter clinical trial

16 September 2017

0 references

1 reference

1 reference

1 reference

17

Lucie Karayan-Tapon

0 references

Tamara Matysiak-Budnik

15

object named as

Tamara Matysiak-Budnik

1 reference

16 September 2017

22

Julien Taïeb

1 reference

16 September 2017

Aziz Zaanan

23

0 references

David Tougeron

object named as

David Tougeron

1

0 references

Dewi Vernerey

19

object named as

Dewi Vernerey

1 reference

16 September 2017

20

Franck Bonnetain

1 reference

16 September 2017

5

Romain Coriat

1 reference

16 September 2017

Guillaume Mouillet

2

1 reference

16 September 2017

Isabelle Trouilloud

3

1 reference

16 September 2017

Thierry Lecomte

4

1 reference

16 September 2017

Thomas Aparicio

6

1 reference

16 September 2017

Gaetan Des Guetz

7

1 reference

16 September 2017

Cédric Lécaille

8

1 reference

16 September 2017

Pascal Artru

9

1 reference

16 September 2017

Gaelle Sickersen

10

1 reference

16 September 2017

Estelle Cauchin

11

1 reference

16 September 2017

David Sefrioui

12

1 reference

16 September 2017

Tarek Boussaha

13

1 reference

16 September 2017

Aurélie Ferru

14

1 reference

16 September 2017

Christine Silvain

16

1 reference

16 September 2017

Jean-Christophe Pagès

18

1 reference

16 September 2017

Pierre Michel

21

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 February 2016

1 reference

Journal of the National Cancer Institute

16 September 2017

1 reference

16 September 2017

108

1 reference

16 September 2017

7

1 reference

16 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Systematic review of microsatellite instability and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuva

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Colon cancer mutation: prognosis/prediction--response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Mismatch repair proficiency and in vitro response to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Adherence to stage-specific treatment guidelines for patients with colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Incidence of Hereditary Nonpolyposis Colorectal Cancer and the Feasibility of Molecular Screening for the Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

Colon Cancer Mutation: Prognosis/Prediction-Letter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV438

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJV438

1 reference

16 September 2017

1 reference